Corporate Member Update: Seattle Genetics

Corporate Member Update: Seattle Genetics

May, 2020

Seattle Genetics is excited to announce the approval of TUKYSA by the U.S. Food and Drug Administration (FDA). TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.

To read the full announcement and important safety information, please click here!

Become a NOS Member Today!

Platinum Corporate Members

Gold Corporate Members